

REMARKS

Interview Summary

Applicants respectfully thank the Examiner for the time that was generously extended during the April 19, 2010 telephonic interview. In response to the interview, the applicants have amended the claims as suggested by the examiner. Specifically, applicants made the following amendments.

Claim 1

Applicants removed the provisos and many compounds from the end of claim 1.

Claim 13

The status of this claim was improperly identified in the prior response. As a result, applicants have resubmitted the amendment, wherein the dependency of the claim was changed from claim 10 to claim 1. Claim 13 was also identified as being "Currently Amended."

Claim 22

Claim 22 has been cancelled.

Claims 23 and 24

The dependencies of these claims was changed from claim 22, now cancelled, to claim 16.

Claim 27

Compounds not encompassed by claim 1 have been removed. The structure for Entry 1, which was inadvertently deleted in the prior response, was re-inserted.

Additionally, the figure in Entry 180 was amended. The –CN group appeared as –NC in the original figure; the new figure clearly shows the proper –CN orientation of the cyano group. Support for this amendment may be found in the name of entry 180, i.e., "... (6-cyanopyridin-..."

Claims 30, 34 and 35

The specific compounds were removed. A typographical error was also corrected.

Claim 33

The following conditions/diseases were added: rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; arteriosclerosis, myocardioinfarction, ischemia, stroke, restenosis; interbowel diseases, osteoarthritis, macular degeneration, or diabetic retinopathy. Support for this amendment may be found in the specification as filed, in paragraph [0020]. "Cancer" was not claimed at the request of the examiner.

The amendments to claim 33 were done for the sole purpose of expediting prosecution and putting the claims in condition for allowance.

Applicants did not use any exhibits during the interview. No prior art was discussed. Claims 1, 13, 23, 24, 27, 30, 33, 34, and 35 were discussed.

No new matter was added.

The Applicants undersigned representative also talked to examiner Bianchi on April 20, 2010 (by phone). Each compound in claim 27 was discussed and the examiner confirmed which compounds should be canceled. It was also noted that claim 27 did not end in a period; thus, a period was added to the end of the claim. No exhibits were used.

Claim 33 was also discussed. Specifically, it was confirmed that "cancer" was not being claimed.

No prior art was discussed.

Applicants preserve the right to prosecute all cancelled claims and deleted subject matter in continuing patent applications.

Conclusion

In view of the foregoing amendments and remarks, Applicants respectfully submit that the present application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,

Date: April 20, 2010

By: /Bradley W. Crawford/
Bradley W. Crawford
Reg. No. 50,494

McDonnell Boehnen
Hulbert & Berghoff LLP
32nd Floor
300 South Wacker Drive
Chicago, IL 60606
Tel: (312) 913-2114 (direct)
Tel: (312) 913-0001 (general)